Sharps Technology (STSS) Registration Filing summary

Company overview and business model

• Designs, patents, and seeks to commercialize safety syringes and innovative drug delivery devices, with a focus on healthcare worker and patient safety, product performance, and quality.

• Owns four issued U.S. patents and several pending applications, with a product portfolio including Securegard, Sologard, and SafeR platforms.

• Manufactures in Hungary, employs 56 full-time staff, and has expanded distribution through agreements with Roncadelle and Stericare Solutions.

• Has not yet generated significant revenue from syringe sales but is building inventory and production capacity to support anticipated orders.

Financial performance and metrics

• Entered into a $50M+ supply agreement with Stericare Solutions for 520 million syringes over five years, with initial deliveries starting November 2024.

• Recent asset purchase agreement with Nephron Pharmaceuticals for $35M plus $4M in assumed liabilities, with a $1M deposit forfeited due to non-consummation by July 2024.

• Raised capital through Regulation A offering in December 2024, issuing 248,430 shares at $1.95 per share for gross proceeds of $484,438.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of 37,013 shares by selling stockholders; any proceeds from other offerings are intended for general working capital.